Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 179 clinical trials
Haplo Peripheral Blood Sct In GVHD Prevention

(MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation

melphalan
cancer
lymphocytic leukemia
myeloproliferative disorder
lymphoid leukemia
  • 0 views
  • 25 Jan, 2021
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

This phase II trial studies how well topotecan hydrochloride and carboplatin with or without veliparib work in treating patients with myeloproliferative disorders that have spread to other

refractory acute myeloid leukemia (aml)
cancer
myeloproliferative/myelodysplastic disorders
myeloproliferative disorder
myelofibrosis
  • 64 views
  • 03 Feb, 2021
  • 2 locations
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm

syndrome or high-risk myeloproliferative neoplasm. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to a chemotherapy drug, called ozogamicin. Gemtuzumab is a form of targeted

cancer
leukemia
acute promyelocytic leukemia
monoclonal protein
myeloid leukemia
  • 5 views
  • 26 Jan, 2021
  • 1 location
Azacitidine Venetoclax and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

This phase I/II trial studies the best dose of venetoclax when given together with azacitidine and pevonedistat and to see how well it works in treating patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor …

blood transfusion
mds/mpn-u
mds/mpn-rs-t
chromosome abnormalities
leukemia
  • 40 views
  • 25 Feb, 2021
  • 1 location
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies

This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating participants with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes …

blast cells
bone marrow procedure
cancer
refractory acute myeloid leukemia (aml)
azacitidine
  • 39 views
  • 03 Mar, 2021
  • 6 locations
Filgrastim Cladribine Cytarabine and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase I/II trial studies the side effects and best dose of filgrastim (granulocyte colony-stimulating factor [G-CSF]), cladribine, cytarabine, and mitoxantrone, when given together with sorafenib and to see how well they work in treating patients with newly-diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (likely to be more aggressive). …

cancer
myeloproliferative disorder
hemolysis
leukemia
acute promyelocytic leukemia
  • 78 views
  • 27 Jan, 2021
  • 1 location
Recombinant Human Interleukin-7 to Promote T-Cell Recovery After Cord Blood Transplant

myeloid leukemia, or myeloproliferative disease after a cord blood transplant. Umbilical cord blood is a source of blood-forming cells that can be used for transplant, also known as a graft. However

filgrastim
myeloproliferative disorder
leukemia
granulocyte colony stimulating factor
graft versus host disease
  • 0 views
  • 31 Jan, 2021
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of inflammation by blocking …

lymphocytic leukemia
leukemia
tocilizumab
myeloid leukemia
residual tumor
  • 71 views
  • 03 Mar, 2021
  • 1 location
Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders

This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with myelodysplastic syndromes, myeloproliferative neoplasms, or related

  • 0 views
  • 03 Mar, 2021
  • 7 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 or IDH2-mutant advanced hematologic malignancies who have received standard therapy

blast cells
IDH2
hematologic malignancy
  • 0 views
  • 18 Feb, 2021
  • 5 locations